Takara Bio Inc. said Wednesday it has agreed in principle to tie up with Italian drug venture MolMed S.p.A. to develop and commercialize three gene therapy techniques. Two of the treatments are for cancer, the other is for AIDS.
The deal will give Takara Bio the exclusive rights across nearly all of Asia to use MolMed’s technologies relating to gene therapy for treating leukemias, lymphomas and myelomas with a gene called HSV-TK, cell lung cancer and other solid tumors using HSV-TK with a gene called MAGE3, and HIV using multiple genes that interfere with HIV replication.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.